From Zacks Investment Research: 2025-05-20 13:24:00

Shares of bioAffinity Technologies, Inc. (BIAF) have risen 0.04% after reporting Q1 2025 earnings of $1.9 million, down 22.9% from the previous year. Despite a 54.7% decline in stock performance over the past month, sales of their CyPath Lung diagnostic surged 276%. Operating expenses increased 2.9% to $4.5 million, with a net loss of $2.7 million. Management emphasized a strategic pivot towards high-margin diagnostics and cost-cutting measures. CEO Maria Zannes highlighted operational progress and recent enhancements in test processing. bioAffinity raised $1.4 million through warrant exercises and $3.3 million via a public offering to support commercialization efforts.

The decline in revenues was offset by a surge in sales of bioAffinity’s flagship diagnostic, CyPath Lung, and a strategic pivot towards high-margin diagnostics. Management emphasized cost-cutting measures and operational improvements to support growth and profitability. The company raised $1.4 million through warrant exercises and $3.3 million via a public offering to support ongoing clinical development and commercialization efforts.



Read more at Zacks Investment Research: BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline – May 20, 2025